PDSB — PDS Biotechnology Share News
0.000.00%
Last trade - 00:00PDS Biotechnology Q3 net loss narrows on lower operating expenses
Brief: PDS Biotechnology Q3 EPS USD -0.19
Brief: PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
Brief: PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
Brief: PDS Biotech Achieves Extended Survival In Low PD-L1 Expression Cohort In VERSATILE-002 Trial For Head & Neck Cancer
Brief: PDS Biotechnology Corp Files For Mixed Shelf Of Up To $200 Million
Brief: Pds Biotech Announces Final Topline Survival Data From Versatile-002 Phase 2 Trial In Head And Neck Cancer
PDS Biotechnology Corp reports results for the quarter ended June 30 - Earnings Summary
PDS Biotechnology Corp expected to post a loss of 23 cents a share - Earnings Preview
PDS Biotechnology Corp expected to post a loss of 23 cents a share - Earnings Preview
PDS Biotechnology Corp reports results for the quarter ended March 31 - Earnings Summary
PDS Biotechnology Corp expected to post a loss of 25 cents a share - Earnings Preview
Brief: Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research
PDS Biotechnology Corp reports results for the quarter ended December 31 - Earnings Summary
Brief: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
PDS Biotechnology Corp expected to post a loss of 28 cents a share - Earnings Preview
Brief: PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer
Brief: PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)